Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + dexamethasone sodium phosphate + methylprednisolone acetate
- Development stage
- Unknown
- Lead developer
- Yale University
- Modality
- Small Molecules
- Administration
- Perineural
01
Overview
B-DEX-MPA is an investigational triple-combination therapy developed by Yale University for the management of post-surgical pain, specifically in patients undergoing total knee arthroplasty (TKA). It consists of the local anesthetic bupivacaine and two corticosteroids: the fast-acting, water-soluble dexamethasone sodium phosphate and the long-acting, depot-formulated methylprednisolone acetate. The combination is administered via peripheral nerve blocks, such as the adductor canal block and iPACK block. Bupivacaine provides immediate analgesia by blocking voltage-gated sodium channels, while the corticosteroids are intended to prolong the duration of the block and reduce local inflammation. This formulation is being evaluated in Phase 2 clinical trials (the Yale SEVEN studies) to compare its efficacy and duration of pain relief against liposomal bupivacaine (Exparel).
- Other names
- Yale SEVEN study drugB-DEX-MPA mixture
02
Targets
NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on bupivacaine + dexamethasone sodium phosphate + methylprednisolone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + dexamethasone sodium phosphate + methylprednisolone acetate.